http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Cho, Sun Young,Kang, Cheol-In,Cha, Min Kyeong,Wi, Yu Mi,Ha, Young Eun,Chung, Doo Ryeon,Lee, Nam Yong,Peck, Kyong Ran,Song, Jae-Hoon Mary Ann Liebert, Inc. Publishers 2015 Microbial Drug Resistance Vol.21 No.4
<P>Despite the remarkable emergence of extended-spectrum -lactamase (ESBL)-producing Escherichia coli sequence type 131 (ST131), the clinical features and outcomes of infections caused by ST131 remain poorly described. From 2011 to 2012, we collected ESBL-producing E. coli isolates from patients with bloodstream infections in 13 hospitals in Korea and compared clinical characteristics and outcomes between ST131 and non-ST131 clones. Of the 110 ESBL-producing isolates, the most common ST was ST131 (30.9%). Multivariate analysis showed that recent operation was the only variable associated with the ST131 clone; other comorbid conditions and clinical features were similar between ST131 and non-ST131 clones. CTX-M-14 and CTX-M-15 were the predominant types of ESBLs, and CTX-M-15 was significantly associated with ST131. The rate of nonsusceptibility to ciprofloxacin was higher in ST131 than in non-ST131 clones (94.1% vs. 75.0%). No significant differences in 30-day mortality rates were found between ST131 and non-ST131 clones. Multivariate analysis revealed that older age (odds ratio [OR]=5.39, 95% confidence interval [CI] 1.22-23.89; p=0.027), nosocomial infection (OR=4.81, 95% CI 1.15-20.15; p=0.032), and higher Pitt bacteremia score (OR=7.26, 95% CI 1.41-37.42; p=0.018) were independent risk factors for 30-day mortality. The ESBL-producing E. coli ST131 clone has emerged and disseminated in Korea. Our findings reveal similarities in clinical and demographic characteristics between ST131 and non-ST131 clones. Although a more resistant profile has been detected in ST131, patients with the ST131 clone did not exhibit a higher mortality rate.</P>
Sun-Ran Cho,Jin-Won Jeong,Youn-Ho Shin,Young-Uk Park,Seung-Hwan Yun,Changmann Yoon,Hyun-Na Koo,Gil-Hah Kim 한국응용곤충학회 2011 한국응용곤충학회 학술대회논문집 Vol.2011 No.05
In this study, we compared global proteome profiles and the expression pattern of defense-related genes in Chinese cabbage when infested by Myzus persicae and Plutella xylostella. Four-week-old Chinese cabbage was exposed to each insect for 24 h, and then proteins and total RNA were extracted from leaves. To elucidate the herbivore-induced differentially expressed proteins in Chinese cabbage, proteins were separated by two-dimensional gel electrophoresis, and visualized by staining with Coomassie G250. Approximately 1600 protein spots were separated and 249 protein spots showed reproducible changes in expression. Among them, nine proteins whose expressions were markedly up-regulated in M. persicae-infested group were identified using matrixassisted laser desorption/ionization time of flight mass spectrometry. The identified herbivore-responsive proteins (ribulose-1,5-bisphosphate carboxylase/ oxygenase, ATP synthase CF1, putative mismatch binding protein Mus3, and integrase core domain-containing protein) were involved in regulation of photosynthesis, carbohydrate metabolism and DNA repair. The expression levels of chitinase, b-1,3-glucanse, peroxidase, PR1, and PR4 in herbivore-infested Chinese cabbage were analyzed by reverse transcription-polymerase chain reaction. The results clarify the response of Chinese cabbage to two herbivore attack at the protein level.
Cho, Hea-Young,Kang, Hyun-Ah,Park, Chan-Ho,Kim, Se-Mi,Kim, Dong-Ho,Park, Sun-Ae,Kim, Kyung-Ran,Hur, Hyeon,Lee, Yong-Bok The Korean Society of Pharmaceutical Sciences and 2005 Journal of Pharmaceutical Investigation Vol.35 No.5
The purpose of the present study was to evaluate the bioequivalence of two torasemide tablets, Torem tablet (Roche Korea Co., Ltd., Korea, reference drug) and Boryung Torsemide tablet (Boryung Pharmaceutical Co., Ltd., Korea, test drug), according to the guidelines of Korea Food and Drug Administration (KFDA). After adding an internal standard (furosemide) to human serum, serum samples were extracted using 5 mL of ethyl acetate. Compounds were analyzed by reverse-phase HPLC method with UV detection. This method showed linear response over the concentration range of 0.05 ug/mL with correlation coefficient of 0.999. The lower limit of quantitation using 0.5 mL of serum was 0.05 ug/mL which was sensitive enough for pharmacokinetic studies. Twenty-eight healthy male Korean volunteers received each medicine at the torasemide dose of 20 mg in a $2{\times}2$ crossover study. There was a one-week washout period between the doses. Serum concentrations of torasemide were monitored by an HPLC-UV for over a period of 12 hr after the administration. $AUC_{t}$(the area under the serum concentration-time curve from time zero to 12 hr) was calculated by the linear trapezoidal rule method. $C_{max}$ (maximum serum drug concentration) and $T_{max}$ (time to reach $C_{max}$) were compiled from the serum concentration-time data. Analysis of variance was carried out using logarithmically transformed $AUC_{t}$ and $C_{max}$. No significant sequence effect was found for all of the bioavailability parameters indicating that the crossover design was properly performed. The 90% confidence intervals of the $AUC_{t}$ ratio and the $C_{max}$ ratio for Boryung Torsemide/Torem were log 0.97-10g 1.03 and log 0.93log 1.12, respectively. These values were within the acceptable bioequivalence intervals of log 0.80-log 1.25. Thus, the criteria of the KFDA guidelines for the bioequivalence was satisfied, indicating Boryung Torsemide tablet and Torem tablet are bioequivalent.